b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="In-Process" Owner="NLM">\n        <PMID Version="1">31172231</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>05</Month>\n            <Day>07</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1432-0827</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>105</Volume>\n                    <Issue>3</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>09</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Calcified tissue international</Title>\n                <ISOAbbreviation>Calcif. Tissue Int.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Cost-Effectiveness of the Screening for the Primary Prevention of Fragility Hip Fracture in Spain Using FRAX<sup>\xc2\xae</sup>.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>263-270</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00223-019-00570-9</ELocationID>\n            <Abstract>\n                <AbstractText>To assess the cost-effectiveness of the primary prevention of fragility hip fractures through opportunistic risk-based screening using FRAX<sup>\xc2\xae</sup> among women aged 70 to 89\xc2\xa0years, and the subsequent treatment with alendronate in women at high-risk, from the Spanish national health system perspective. We performed a discrete-event simulation model. Women were categorized in low, intermediate and high-risk of fragility hip fracture through screening based on the FRAX<sup>\xc2\xae</sup> risk assessment tool score (Spanish version). Low-risk women received lifestyle recommendations whereas the high-risk group was assigned to alendronate treatment. For women at intermediate-risk, treatment decision was based on a recalculated score considering bone mineral density (BMD). The cost-effectiveness analysis tested six scenarios defined by different FRAX<sup>\xc2\xae</sup> cut-off values assessing the incremental costs per averted fracture in 20\xc2\xa0years. Deterministic sensitivity analysis was performed. We included a random sample of 5146 women obtained from a Spanish cohort of women referred for BMD. The most cost-effective intervention had an Incremental Cost-effectiveness Ratio (ICER) of 57,390 \xe2\x82\xac per averted hip fracture and consisted of using the FRAX<sup>\xc2\xae</sup> score without BMD and treating women with a score higher than 5%. The ICER exceeded the acceptability threshold of 25,000 \xe2\x82\xac in all the scenarios. Sensitivity analysis based on time to fracture, treatment efficacy, adherence to treatment and cost of dependence resulted in ICERs ranging from 39,216 \xe2\x82\xac to 254,400 \xe2\x82\xac. An ICER of 24,970 \xe2\x82\xac was obtained when alendronate cost was reduced to 1.13 \xe2\x82\xac per month. The use of FRAX<sup>\xc2\xae</sup> as screening tool followed by alendronate treatment is not cost-effective in senior women in Spain. Other primary preventions strategies are advisable.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Martin-Sanchez</LastName>\n                    <ForeName>Mario</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Preventive Medicine and Public Health Training Unit PSMAR-UPF-ASPB (Parc de Salut Mar - Pompeu Fabra University-Public Health Agency of Barcelona), Barcelona, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Comas</LastName>\n                    <ForeName>Merc\xc3\xa8</ForeName>\n                    <Initials>M</Initials>\n                    <Identifier Source="ORCID">0000-0003-1926-2740</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. mcomas@parcdesalutmar.cat.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Red de Investigaci\xc3\xb3n en Servicios de Salud en Enfermedades Cr\xc3\xb3nicas (REDISSEC), Barcelona, Spain. mcomas@parcdesalutmar.cat.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Posso</LastName>\n                    <ForeName>Margarita</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Red de Investigaci\xc3\xb3n en Servicios de Salud en Enfermedades Cr\xc3\xb3nicas (REDISSEC), Barcelona, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Louro</LastName>\n                    <ForeName>Javier</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Red de Investigaci\xc3\xb3n en Servicios de Salud en Enfermedades Cr\xc3\xb3nicas (REDISSEC), Barcelona, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Domingo</LastName>\n                    <ForeName>Laia</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Red de Investigaci\xc3\xb3n en Servicios de Salud en Enfermedades Cr\xc3\xb3nicas (REDISSEC), Barcelona, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Teb\xc3\xa9</LastName>\n                    <ForeName>Cristian</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Castells</LastName>\n                    <ForeName>Xavier</ForeName>\n                    <Initials>X</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Red de Investigaci\xc3\xb3n en Servicios de Salud en Enfermedades Cr\xc3\xb3nicas (REDISSEC), Barcelona, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Espallargues</LastName>\n                    <ForeName>Mireia</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Red de Investigaci\xc3\xb3n en Servicios de Salud en Enfermedades Cr\xc3\xb3nicas (REDISSEC), Barcelona, Spain.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Ag\xc3\xa8ncia de Qualitat i Avaluaci\xc3\xb3 Sanit\xc3\xa0ries de Catalunya (AQuAS), Barcelona, Spain.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D013485">Research Support, Non-U.S. Gov\'t</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>06</Month>\n                <Day>06</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Calcif Tissue Int</MedlineTA>\n            <NlmUniqueID>7905481</NlmUniqueID>\n            <ISSNLinking>0171-967X</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">Dxa</Keyword>\n            <Keyword MajorTopicYN="Y">Fracture prevention</Keyword>\n            <Keyword MajorTopicYN="Y">Health economics</Keyword>\n            <Keyword MajorTopicYN="Y">Osteoporosis</Keyword>\n            <Keyword MajorTopicYN="Y">Screening</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>03</Month>\n                <Day>07</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>05</Month>\n                <Day>30</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>6</Month>\n                <Day>7</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>6</Month>\n                <Day>7</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>6</Month>\n                <Day>8</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31172231</ArticleId>\n            <ArticleId IdType="doi">10.1007/s00223-019-00570-9</ArticleId>\n            <ArticleId IdType="pii">10.1007/s00223-019-00570-9</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'